ST131-H30 was responsible for 5.3% of all extraintestinal E. coli infections and 43.3% of ESBL-producing extraintestinal E. coli infections among US children. The clinical and demographic correlates of infection with ST131-H30 differed between extended-spectrum cephalosporin-resistant and -sensitive isolates.
INTRODUCTION
Extraintestinal Escherichia coli, a common cause of urinary tract and bloodstream infections across all ages, have displayed increasing rates of antimicrobial resistance over the past two decades.
[1] This increase has been attributed to the emergence and rapid clonal expansion of E. coli Sequence Type (ST) 131, which has transformed the population structure of extraintestinal E. coli infections worldwide. [2] [3] [4] [5] Molecular epidemiologic studies have shown that a subclone of ST131, termed H30, has driven the global dissemination of ST131. [6] [7] [8] [9] The clonal structure of ST131-H30 is tightly linked to antimicrobial resistance; the vast majority of H30 isolates are fluoroquinolone resistant due to mutations in the gyrA and parC chromosomal genes (isolates known as H30-R or clade C), while nested subclones are additionally associated with the production of CTX-M-type extended-spectrum beta-lactamases (ESBLs) that confer resistance to extended-spectrum cephalosporins ( Figure S1 ). [7, 8, [10] [11] [12] Although E. coli ST131-H30 (hereafter, H30) has been recognized as a clone of significant public health importance, [5, 13] there is a lack of data about its epidemiology in children. Most studies that have included H30 isolates from children have occurred over short time periods at single centers and have accumulated few H30 isolates. [14] [15] [16] Among adults in the US, H30 is estimated to comprise about 50% of ESBL-producing E. coli infections and 10%-20% of all extraintestinal E. coli infections, and has been linked to host factors including older age, healthcare contact, local or systemic compromise, and recent antibiotic use. [6, [14] [15] [16] [17] Associations with adverse outcomes such as persistent infections, new infections, sepsis, and hospitalization have also been reported in adult populations. [7, 14, 18] Understanding the epidemiology of H30 in pediatric populations is important, as its dominance among multidrugresistant (MDR) extraintestinal E. coli makes it a likely culprit of many difficult-to-treat infections in children. Proper treatment of urinary tract infections -the most common type of infection caused by extraintestinal E. coli -is especially critical in pediatric populations, as young children are more prone to upper urinary tract infection with potential short-and long-term complications such as renal scarring and decreased renal function. [19, 20] We sought to address this knowledge gap using data from a multiyear, multicenter prospective case-control study of extraintestinal E. coli infections to quantify the burden and identify clinical and demographic correlates of infection with H30 in a US pediatric population. In addition, we describe and compare the antimicrobial resistance characteristics of H30 and non-H30 E. coli isolates.
METHODS

Patients and isolates
All isolates and clinical data came from a multicenter case-control study that prospectively collected isolates and is described in detail elsewhere. [21] (ESC-S) isolates, were collected without respect to any patient or microbiological characteristics beyond temporal proximity to the ESC-R isolates and prior enrollment in the study (patients could only contribute one ESC-S isolate). Demographic and clinical data were collected from the medical records; methods for categorizing underlying medical conditions, capturing antibiotic exposure, and characterizing the clinical significance of urine isolates (likely UTI vs. not) were described previously. [21, 22] The Institutional Review Board at each hospital approved the study protocol.
Laboratory methods
Methods for antibiotic susceptibility testing and typing of resistance phenotypes and determinants were described previously. [21] Briefly, ESC-R phenotypes (ESBL vs. AmpC) were characterized using a combination of disk diffusion and E-tests. Genetic determinants of extended-spectrum cephalosporin resistance were identified by PCR using primers for genes encoding common extended-spectrum cephalosporinases. [21] H30 isolates were identified using the fumC/fimH genotyping scheme. [23] Isolates belonging to the H30Rx sublineage were identified by PCR detection of sublineage-specific single nucleotide polymorphisms. [7] Statistical analyses
Prevalence estimates
The period prevalence of H30 was estimated by calculating a weighted average of the ESC-R and ESC-S stratum-specific prevalence estimates (details in Supplementary Methods).
Host correlates of infection
Only the first isolate from each unique individual was considered in the host factor analyses.
Host factors were compared between patients with H30 vs. non-H30 isolates, stratified by ESC-R status and adjusting for study hospital where sample size allowed. The magnitude of the association between each predictor of interest and H30 infection was then assessed using univariable and multivariable log-binomial regression models. For each predictor of interest, the relative risk (RR) and 95% confidence intervals (CIs) from three models are presented: 1) a univariable model that estimates the crude (unadjusted) total effect of the predictor of interest on the outcome; 2) a multivariable model that estimates the total effect of the predictor of interest on the outcome, adjusted for potential confounders; and 3) a multivariable model that estimates the direct effect of the predictor of interest on the outcome, adjusted for potential confounders as well as for potential mediators. All multivariable models adjusted for study hospital; additional potential confounders and mediators were selected according to the conceptual frameworks found in the supplementary material ( Figures S3 & S4 ). Finally, we conducted post-hoc analyses of the interaction between age and underlying medical condition (details in Supplementary Methods).
Antimicrobial resistance characteristics
We examined co-resistance to commonly used antimicrobial agents in the first E. coli isolate collected per individual, stratifying by ESC-R and ESC-S status to maintain consistency with the sampling scheme of the parent study. H30 isolates were additionally stratified into H30Rx and H30-non-Rx ( Figure S1 ) and compared to non-H30 isolates. Among ESC-R isolates, ESC-Rassociated resistance mechanisms and determinants were also identifed and compared. All analyses were conducted using R version 3.3.1 (R Core Team, 2016).
RESULTS
Isolates and prevalence estimates
A total of 339 ESC-R isolates from 278 patients and 1008 ESC-S isolates from 1008 patients were available for analyses ( Figure S2 ). The estimated prevalence of H30 among all clinical E. coli isolates at all study hospitals was 5.3% (95% CI 4.6%-7.1%), while the hospital-specific prevalence ranged from 2.7% to 6.2% (Figure 1 ). The estimated overall prevalence of H30Rx was 0.87% (95% CI 0.70%-1.7%).
Host correlates of infection by ESC-R status
The first ESC-R isolate from each of the 278 patients with an ESC-R isolate collected during the study period was included in the host correlates analyses ( Figure S2 ). Among these patients, patient age was associated with H30 infection and further examined as a predictor of interest (Table 1) . Our sample size precluded multilevel predictors, so age was categorized into ages 0-5 versus 6-21 years in regression models. After adjusting for potential confounders, age 0-5 was associated with an 83% increased risk of the infecting organism being H30 (RR 1.83, 95%CI 1.19-2.83). There was no evidence that this association was mediated through factors related to underlying illness, or that underlying illness interacted with age ( Table 3 and Table S3 ). When restricting the outcome to H30Rx infection only (vs. non-H30 infection) and adjusting for potential confounders, the effect size was stronger (RR 2.25, 95%CI 1.33-3.80).
A total of 1008 patients had one ESC-S isolate collected during the study period. Among these patients, patient age and several factors associated with underlying illness were associated with H30 infection (Table 1) . Each of these variables was examined as a predictor of interest except for: (i) history of transplantation, due to small numbers, and (ii) type of infection acquisition, since previous hospitalization and underlying medical conditions were examined independently.
Underlying medical condition and indwelling device categories were collapsed into any vs. none. (Table S4 ). When including potential mediators in the models, the magnitude of the associations between age ≤ 5 years and presence of an underlying medical condition with H30 infection decreased, but the associations remained statistically significant ( Table 3 ). Evidence of interaction between age and underlying medical condition was observed; when examining joint effects, underlying medical condition was only significantly associated with H30 infection in combination with older age, and older age was only significantly associated with H30 infection in combination with presence of an underlying medical condition (Table 4 ).
Patient age
Since patient age was important in the analyses of both ESC-R and ESC-S isolates, we also visually inspected the distributional differences of age measured continuously. While the non-H30 age distributions are very similar, the H30 age distributions display marked differences between ESC-R and ESC-S isolates ( Figure 2 ).
Antimicrobial resistance characteristics by ESC-R and H30Rx status
A total of 278 ESC-R isolates were examined (the first isolate collected per individual). Among these isolates, nearly all H30Rx and H30-non-Rx isolates were non-susceptible to fluoroquinolones, compared to less than half of non-H30 isolates (Table 2) . Similarly, all ESC-R H30Rx and the vast majority of H30-non-Rx isolates were ESBL-producing, while non-H30 isolates were more evenly split between ESBL producers and AmpC producers. H30 was the most common subclone identified among the ESC-R isolates in the study (Table S1) (Table 2 ). Systematic differences in the types of ESC-R resistance determinants by study hospital or year were not observed ( Figure   S5 ).
Among the 1008 ESC-S isolates examined, fluoroquinolone non-susceptibility was dominant among H30 isolates, while only a small fraction of non-H30 ESC-S isolates were nonsusceptible to fluoroquinolones (Table 2) .
DISCUSSION
We utilized a multiyear, multicenter case-control study of extraintestinal E. coli infections in children's hospitals to address a critical knowledge gap about the epidemiology of the globally important ST131-H30 subclone among US children. Our results can be summarized into three main findings. First, the estimated prevalence of H30 among pediatric extraintestinal E. coli isolates of 5.3% was lower than the 10-20% that has been observed in US adults. [6, 14, 15] However, H30 was nearly as dominant among ESBL-producing isolates in children (43.3%) as has been reported in adults (about 50%). [16, 17] Other studies have suggested that H30 is less prevalent among children than adults; however, very few pediatric isolates were included in these studies. [15, 16] Interestingly, we observed that H30 was nearly as dominant among ESBL-producing E. coli infections in children as has been reported in adults. [16, 17] These findings are consistent with a recent study from a pediatric setting conducted in the Midwestern US. [25] However, in the context of all clinical extraintestinal E. coli infections, ESBL-producing organisms are still relatively rare in both adults and children.
The bulk of the H30 isolates circulating in the population are non-ESBL-producing but fluoroquinolone-resistant, and these isolates were much less common in our study than has been observed in adult populations. [15, 16] This observation may be explained by differential antibiotic use in these populations. Fluoroquinolones are infrequently prescribed to children due to concerns about toxicity; [26] in our study, about 5% of patients received fluoroquinolones in the year before collection of their first isolate, while 46% of patients received any antibiotic in that same time period ( Figure S6 ). Lower rates of fluoroquinolone use likely translate to less selective pressure on fluoroquinolone-resistant organisms such as H30. Interestingly, a recent study conducted in adults in Australia and New Zealand, a population that also has low rates of fluoroquinolone use, reported an overall prevalence of H30 of 3.5%, but a prevalence of H30 among ESC-R E. coli of 39%, which is similar to our findings. [27] The association we identified between H30 and young age among ESC-R isolates is consistent with the findings of a recent longitudinal study showing that among children, the prevalence of ESBL-producing Enterobacteriaceae was highest and increasing most rapidly in children aged 1-5. [28] Why H30/H30Rx is more frequently found among young children with ESC-R infections compared to older children with ESC-R infections, as well as where young children are acquiring this pathogen, deserves further investigation. Previous studies have portrayed H30 as an opportunistic pathogen that favors compromised hosts including the elderly, [14] and young children's developing immune systems could be associated with H30 infection. Maternal infection or colonization may also play a role; a recent study found H30 colonization during the first several years of life of healthy twins was associated with the mother also being colonized, however, none of these H30 isolates were ESBL-producing. [29] Finally, while transmission of H30 between children within healthcare facilities has not been documented, there are reports of transmission of, and persistent colonization with, H30/H30Rx among healthy children within daycares and households. [29] [30] [31] [32] Future studies might focus on systematic sampling in the community setting in order to better elucidate the reservoirs and transmission dynamics of H30/H30Rx among young children.
The association we observed between ESC-S H30 infections and older children is not consistent with the limited existing data. [15, 33] . Our post-hoc interaction analyses suggest that age and underlying illness interact, with the strongest risk of an infection being H30 observed in older children with underlying medical conditions. We hypothesize that these observed associations could be driven by different selective pressures in older, less healthy children: specifically, fluoroquinolones are likely prescribed more frequently to older children than younger children due to less concern about toxicity. This prescribing pattern was borne out in our data; the median age was 12.6 years among patients that received fluoroquinolones in the year prior to their infection, whereas the median age among those that received any antibiotic was 6 years ( Figure S6) . A more refined examination of the role of antibiotic exposure, specifically focusing on fluoroquinolones, is warranted.
Notably, previous studies conducted in adult populations have described H30 as being associated with healthcare contact and compromised hosts, [14, 15] however, we found those associations only among ESC-S H30 infections. The fact that we observed these patterns among ESC-S isolates is not surprising; compromised hosts and healthcare contact are consistently associated with antimicrobial resistant infections, [34] and as is shown in Table 2 , A number of limitations need to be considered in the interpretation of these data. First, because of the case-control design of the parent study, the prevalence of H30 and H30Rx among clinical E. coli isolates could not be calculated directly. However, we believe the assumptions employed in our prevalence estimates are reasonable, and that these data provide the best estimate of the prevalence of H30 in children to date. The design of the parent study was also a strength, as it allowed us to enrich the collection with the less common MDR isolates and examine risk factors for infection with H30 among those with ESC-R E. coli isolates specifically. Second, because this study was an exploratory investigation of an existing dataset, all findings should be interpreted cautiously; there could be residual confounding due to unmeasured or incompletely measured variables, spurious associations identified due to multiple testing, or missed associations due to lack of power. To mitigate this, we attempted to make thoughtful model building decisions and interpretations by using conceptual models rather than taking a purely data-driven approach. Third, the isolates did not undergo multilocus sequence-typing (MLST) or other molecular characterization relevant to H30 such as typing of the gyrA and parC alleles.
However, the H30 isolates in this study have since undergone whole genome sequencing, and in silico MLST analyses have confirmed that isolates classified as H30 are ST131 (data not shown). Finally, although this was a multicenter study, our data were collected from freestanding children's hospitals between 2009 and 2013, so the results may not be generalizable to other settings, and epidemiologic patterns may have shifted during the subsequent several years. Despite these limitations, this study significantly improves our understanding of the impact of H30 in children, and is one of the most robust examinations of the clinical burden of, and risk factors for, H30 infections to date.
Conclusion
Although E. coli ST131-H30 is not as prevalent among children as has been reported in adults, <0.001* <0.001* 1.000 0.046* 0.292 --1.000 0.060 0.037* <0.001* 1.000 1.000 --0.531
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-a P-values generated via Chi-square test; Fisher's Exact test was used when expected frequencies were below 5. b TMP/SMX = trimethoprimsulfamethoxazole c One of these isolates had both a CTX-M-15 gene identified as well as a KPC-3 carbapenemase gene, and was resistant to meropenem. d Total exceeds 100% as isolates could have more than one determinant identified. * p-value < 0.05 
